Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education.

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Degree

Medical Specialty

Submit

Key Decisions in HIV Care: Weight Gain in ART

Source: Key Decisions in HIV Care

Listen as Joseph J. Eron, Jr., MD, explores whether weight gain should or should not be a factor in determining initial therapy.

Joseph J. Eron, Jr., MD

Released: August 30, 2021

In this episode, Joseph J. Eron, Jr., MD, explores whether weight gain should or should not be a factor in determining initial therapy.

Listen as he gives his perspectives on:

Weight gain following ART initiation by ARV class and ARV drug
Results of the ADVANCE and GEMINI-1 and -2 studies, with exploration of weight, risk of CVD and diabetes
BMI changes in PWH
DHHS and IAS-USA guidelines for initial therapy

Information on this Educational Activity

Faculty

Joseph J. Eron, Jr., MD

Professor of Medicine and Epidemiology
University of North Carolina School of Medicine
Director, AIDS Clinical Trials Unit
University of North Carolina
Chapel Hill, North Carolina

Joseph J. Eron, Jr., MD, has disclosed that he has received consulting fees from Gilead Sciences, Janssen, Merck, Trio Health, and ViiV and funds for research support from Gilead Sciences, Janssen, and ViiV.

Program Medium

This program has been made available online.

Acknowledgements

Educational grant provided by:

Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
ViiV Healthcare